Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
2011

Pralatrexate's Effectiveness in Cancer Treatment

Sample size: 15 publication Evidence: high

Author Information

Author(s): Serova M, Bieche I, Sablin M-P, Pronk G J, Vidaud M, Cvitkovic E, Faivre S, Raymond E

Primary Institution: INSERM U728, RayLab, and Departments of Medical Oncology, Beaujon University Hospital, Assistance Publique – Hôpitaux de Paris, Paris 7 Diderot, France

Hypothesis

What are the molecular correlates of sensitivity to pralatrexate in cancer cells?

Conclusion

Pralatrexate was found to be more potent than methotrexate in various solid tumor lines, suggesting its potential for further clinical development.

Supporting Evidence

  • Pralatrexate showed a similar pattern of cytotoxicity to methotrexate but was more potent.
  • The study identified two distinct groups of cancer cell lines based on their sensitivity to pralatrexate.
  • Pralatrexate's effectiveness was correlated with high mRNA expression of FPGS.
  • Acquired resistance to pralatrexate was linked to decreased RFC-1 expression.

Takeaway

Pralatrexate is a medicine that works better than another similar medicine called methotrexate in fighting certain types of cancer cells.

Methodology

The study evaluated the antiproliferative effects of pralatrexate in 15 human cancer cell lines using the MTT assay and gene expression analysis with qRT-PCR.

Limitations

The study used unpurified media which may have theoretically reduced drug activity.

Participant Demographics

The study involved various human cancer cell lines including colon, breast, melanoma, NSCLC, ovarian, prostate, and head and neck cancers.

Statistical Information

P-Value

p<0.01

Confidence Interval

95% confidence interval

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606063

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication